Unity Biotechnology, Inc. (LON:0YC0)

Market Cap	1.41M
Revenue (ttm)	n/a
Net Income (ttm)	-21.29M
Shares Out	n/a
EPS (ttm)	-1.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,370
Average Volume	54,215
Open	0.1051
Previous Close	0.1100
Day's Range	0.1043 - 0.1131
52-Week Range	0.1002 - 3.0400
Beta	n/a
RSI	20.80
Earnings Date	Jul 22, 2025

About Unity Biotechnology

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2009
• Employees: 16
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0YC0

Financial Performance

Financial numbers in USD